Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 671
Out of 4,827 analysts
141
Total ratings
54.46%
Success rate
30.68%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.03 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $13.08 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $540.48 | +57.27% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.46 | +3,783.50% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $2.00 | +2,893.12% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.10 | +190.32% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $6.69 | +408.22% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $118.60 | +175.72% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $3.13 | +858.47% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $0.80 | +8,736.34% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $428.00 | -34.35% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.79 | +186.74% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.01 | +9,602.97% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $272.60 | +8.22% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $97.24 | -11.56% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $34.50 | +39.13% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $8.01 | +274.77% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $28.48 | +152.81% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.17 | +329.18% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $59.23 | +68.83% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $159.66 | +25.89% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $41.56 | +104.55% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $8.11 | +294.57% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $36.74 | +490.64% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $19.64 | +144.40% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $11.43 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $257.70 | -40.24% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $60.59 | +91.45% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $3.03 | +3,398.35% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $8.11 | +245.25% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $200.80 | -59.16% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $309.24 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.63 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.03
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.08
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $540.48
Upside: +57.27%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.46
Upside: +3,783.50%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $2.00
Upside: +2,893.12%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.10
Upside: +190.32%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.69
Upside: +408.22%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $118.60
Upside: +175.72%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $3.13
Upside: +858.47%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $0.80
Upside: +8,736.34%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $428.00
Upside: -34.35%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $2.79
Upside: +186.74%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.01
Upside: +9,602.97%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $272.60
Upside: +8.22%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $97.24
Upside: -11.56%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $34.50
Upside: +39.13%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $8.01
Upside: +274.77%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $28.48
Upside: +152.81%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.17
Upside: +329.18%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $59.23
Upside: +68.83%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $159.66
Upside: +25.89%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $41.56
Upside: +104.55%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $8.11
Upside: +294.57%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $36.74
Upside: +490.64%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $19.64
Upside: +144.40%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $11.43
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $257.70
Upside: -40.24%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $60.59
Upside: +91.45%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $3.03
Upside: +3,398.35%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $8.11
Upside: +245.25%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $200.80
Upside: -59.16%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $309.24
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $1.63
Upside: -